Table 1.
Binding of GLPB30 variants to various length G4S peptides determined by BLI.
| Peptide (AA length) | mAb KD (nmol/L) | BsAb1 KD (nmol/L) | BsAb2 KD (nmol/L) |
|---|---|---|---|
| GGGGSGGGGGSGGGGSGGGGS (20) | 3.6 | 0.4 | 1.6 |
| GGGGSGGGGGSGGGGSGGGG (19) | 2.4 | 0.4 | 1.6 |
| GGGGSGGGGGSGGGGSGGG (18) | 2.5 | 0.2 | 1.3 |
| GGGGSGGGGGSGGGGSGG (17) | 2.5 | 0.2 | 1.3 |
| GGGGSGGGGGSGGGGSG (16) | 4.0 | 0.5 | 3.9 |
| GGGGSGGGGGSGGGGS (15) | 8.2 | 3.1 | 13.7 |
| GGGGSGGGGGSGGGG (14) | 9.4 | 6.4 | 21.4 |
| GGGGSGGGGGSGGG (13) | 7.9 | 5.7 | 25.9 |
| GGGGSGGGGGSGG (12) | 8.1 | 5.7 | 27.4 |
| GGGGSGGGGGSG (11) | 15.6 | 7.3 | 41.7 |
| GGGGSGGGGGS (10) | 18.3 | 7.4 | 40.0 |
NOTE: Binding was determined for GLPB30 formatted as a human IgG1 mAb, a BsAb with GLPB30 as the ScFv fused to the IgG1 C-terminus (BsAb2) or as the Fab arms of a BsAb containing a C-terminal ScFv (BsAb1). No binding was observed for G4S peptides shorter than 10 amino acids in length.